Stelo will be the first glucose biosensor in the US cleared for use without a prescription Indicated for use for people 18 years and older who are not using insulin therapy A small, wearable sensor ...
At ATTD 2026, Dexcom (Nasdaq:DXCM) outlined a range of ways in which its continuous glucose monitors (CGMs) benefit people ...
Now through Sept. 19, people in the U.S. and Canada from 2 years and older living with all types of diabetes and prediabetes can apply for a once-in-a-lifetime opportunity to raise diabetes awareness ...
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2024 financial results after market close on Thursday, July 25, 2024. Management will ...
Sourced from the diabetes community at large through an open call earlier this year, the 16 selected advocates represent strength, advocacy and pride in living with Type 1, Type 2 and prediabetes ...
DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, will present new findings that showcase the benefits of its glucose biosensing technology for people with all types of diabetes and ...
DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose biosensing, today announced the promotion of Jake Leach to president, in addition to his current role as chief operating ...
New RAMQ coverage means eligible Québec residents with type 2 diabetes on intensive insulin therapy can now access Dexcom Continuous Glucose Monitoring (CGM) to simplify diabetes management. Dexcom, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results